Related by context. All words. (Click for frequent words.) 71 ADVANCE PD 70 phase IIIb 70 dose escalation phase 70 Phase IIIb clinical 70 riociguat 70 multicenter Phase II 70 oral methylnaltrexone 69 Randomized controlled 69 blinded randomized placebo controlled 69 phase Ib 69 Phase #b/#a 69 relapsed MM 69 Phase 1a clinical 69 CHAMPION PCI 68 phase IIa 68 PRIMO CABG 68 Phase Ib clinical 68 MAGE A3 ASCI 68 preclinical efficacy 68 STRIDE PD 68 Phase IIb III 68 confirmatory clinical 68 aplindore 68 postapproval 68 balsalazide tablet 68 RSD# oral 68 Phase IIB 68 GSK# [001] 67 placebo controlled clinical 67 Zemplar Capsules 67 active comparator 67 Proellex TM 67 designated HVTN 67 MEND CABG 67 pivotal bioequivalence 67 randomized crossover 67 preclinical pharmacokinetic 67 fosbretabulin 67 clevidipine 67 bioequivalency 67 CIMZIA TM certolizumab pegol 67 lomitapide 67 Androxal TM 67 multicenter Phase III 67 pharmacokinetics PK 67 Phase IIIb study 67 GAMMAGARD 67 EXPLORE Xa 67 randomized controlled multicenter 67 BrachySil TM 66 pharmacokinetic PK study 66 oral rivaroxaban 66 registrational Phase 66 ascending dose 66 phase IIa clinical 66 NATRECOR ® 66 phase Ib clinical 66 pharmacodynamic PD 66 randomized Phase IIb 66 pharmacokinetic pharmacodynamic 66 bovine thrombin 66 icatibant 66 Zenvia Phase III 66 HuMax EGFr 66 genotoxicity reproductive toxicology 66 NP2 Enkephalin 66 GLP toxicology studies 66 dose cohort 66 dose escalation clinical 66 brivaracetam 66 teriflunomide 66 multicenter randomized placebo controlled 66 neratinib 66 Thorough QT 66 visilizumab 66 dose titration 66 Plenaxis TM 66 BETAS 66 ritonavir boosted 65 budesonide foam 65 CALGB # [002] 65 TASKi3 65 MGd 65 Phase IIa trials 65 Secondary efficacy endpoints 65 APEX PD 65 YONDELIS 65 phase IIb clinical 65 prospective randomized multicenter 65 Trandolapril 65 forodesine 65 TQT 65 prucalopride 65 Primary endpoints 65 pharmacokinetics pharmacodynamics 65 ORENCIA ® 65 placebo controlled Phase III 65 Forodesine HCl 65 prospective nonrandomized 65 galiximab 65 PEARL SC 65 prospective multicenter study 65 trastuzumab emtansine T DM1 65 CIMZIA ™ 65 LAB CGRP 65 pharmacokinetic PK profile 65 PSMA ADC 65 midstage clinical 65 AIR CF1 65 CIMZIA TM 65 Dextofisopam 65 randomized multicenter trial 65 double blinded randomized 65 IMPACT DCM 65 Phase IIIb 65 Phase Ib II 65 Tarceva TM 65 treatment naive genotype 65 AGHD 65 MERLIN TIMI 65 hyperphenylalaninemia HPA due 64 HCV RESPOND 2 64 sitaxsentan 64 SNT MC# 64 clinical pharmacology studies 64 migraine prophylaxis 64 alvespimycin 64 pain palliation 64 REMINYL ® 64 gadobutrol 64 CG# [003] 64 double blinded placebo 64 multicenter randomized controlled 64 EchoCRT 64 azilsartan medoxomil 64 pharmacokinetic parameters 64 multicentre randomized 64 nonrandomized 64 Phase III multicenter 64 trastuzumab DM1 T DM1 64 ASCEND HF 64 PrevOnco ™ 64 intermittent dosing 64 tramiprosate Alzhemed TM 64 desvenlafaxine succinate 64 CEQ# 64 randomized blinded 64 phase IIb 64 cardiac repolarization 64 Aryplase 64 Vernakalant 64 pharmacologic stress 64 phase IIb study 64 pharmacodynamics PD 64 Phase IIb clinical trials 64 REVIVE Diabetes 64 inhalation toxicity 64 endothelin antagonists 64 ZACTIMA 64 reslizumab 64 Phase 2a trial 64 CARE HF 64 pharmacodynamic effects 64 ONTARGET 64 OvaRex ® MAb 64 MVax 64 QT QTc 64 NATRECOR R 64 Phase 1b clinical 64 canakinumab 64 MYCAMINE 64 interferon gamma 1b 64 UPLYSO 64 refractory CLL 64 retrospective observational study 64 phase IIb III 64 EmbraceAC 64 HCV SPRINT 64 CBLC# 64 ATACAND 64 VA# [002] 64 blinded randomized 64 Pyridorin 64 crizotinib PF # 64 budesonide MMX Phase III 64 inhaled AAT 64 corticosteroid dose 64 Twinrix 64 im peramivir 64 prospective multicenter 64 Urocortin 2 64 dose proportionality 64 MEND CABG II 64 Phase Ib study 64 viral kinetics 64 ACTEMRA TM 64 Dacogen injection 64 NO# [002] 64 LB# [003] 63 Pharmacokinetic studies 63 VP# [004] 63 placebo controlled Phase 63 PrevOnco 63 dacetuzumab 63 #I TM# 63 multicenter randomized clinical 63 CRMD# 63 dosing cohort 63 novel VDA molecule 63 recurrent glioblastoma multiforme 63 Diamyd r 63 CINQUIL 63 tolerability pharmacokinetics 63 ARCOXIA 63 Pharmacodynamic 63 Prosaptide 63 genotypic resistance 63 RHUCIN 63 intravenous dosing 63 TLK# 63 Arranon 63 synthetic retinoid 63 relapsed MCL 63 subcutaneous methylnaltrexone 63 vernakalant hydrochloride 63 JAK inhibitor 63 PFO migraine 63 ZOLINZA 63 ORENCIA R 63 ongoing Phase 1b 63 HF ACTION 63 pregabalin Lyrica 63 Traficet EN 63 PREZISTA r 63 BRIM3 63 trastuzumab Herceptin ® 63 Teriflunomide 63 bicifadine 63 tacrolimus ointment 63 Phase #/#a 63 pharmacokinetic PK 63 Anturol TM 63 elotuzumab 63 Pivotal Phase III 63 OMS# 63 AeroLEF TM 63 ONCONASE R 63 APEX AMI 63 placebo controlled clinical trials 63 Tasigna prolongs 63 Phase IIA 63 mg/m2 cohort 63 investigational protease inhibitor 63 COSIRA trial 63 TBC# 63 MIRCERA 63 TMC# C# 63 evaluating Actimmune 63 BRIM2 63 hoFH 63 Tolvaptan 63 prospective observational studies 63 PDE4 inhibitor 63 Stedivaze 63 AVERROES 63 PrandiMet TM 63 Phase 2b kidney transplant 63 cannabinor 63 masked placebo controlled 63 Zenvia ™ 63 Bayer HealthCare Onyx Pharmaceuticals 63 Triapine R 63 ORMD 63 ExTRACT TIMI 63 kidney urologic 63 dose escalation Phase 63 oral prodrug 63 PHX# 63 AST ALT 63 Cloretazine 63 ASSERT trial 63 Lixivaptan 63 placebo controlled multicenter 63 dextofisopam 63 LymphoStat B Phase 63 erythropoietic 63 multicenter clinical 63 urocortin 2 63 Aflibercept 63 INS# [001] 63 serum phosphorous 63 urinary N telopeptide 63 Silodosin 63 randomized multicenter 63 acyclovir Lauriad R 63 albiglutide 63 DEB# 63 Initiated Phase 63 OBPM 63 thorough QTc 63 GH deficiency 63 oxymorphone ER 63 Temsirolimus 63 INTERCEPT platelets 63 prospective multicentre 63 controlled multicenter 63 pharmacokinetic equivalence 63 QTc 63 symptomatic paroxysmal AF 63 Alvesco R 63 Phase IIIB IV 63 IIa trials 63 sodium phenylbutyrate 63 T Pred 63 PRTX 63 plasma pharmacokinetics 63 EXPAREL ™ 63 renoprotective 63 haematologic 63 epoetin alpha 62 opioid induced bowel dysfunction 62 Kahalalide F 62 herpetic keratitis 62 catheter occlusion 62 Multiple Ascending Dose 62 LUMINATE 62 ruxolitinib 62 APTIVUS 62 ICA # 62 NOX E# 62 Known hypersensitivity 62 prokinetic agent 62 BoNTA 62 Onrigin 62 tolevamer 62 safety tolerability pharmacokinetic 62 ASPIRE HIGHER 62 GRNVAC1 62 ADMIRE HF 62 telaprevir dosing 62 BAL# [002] 62 DDP# 62 CYT# QbG# 62 tasimelteon 62 EURIDIS 62 antiepileptics 62 Spiegelmer ® 62 phase IIb trial 62 meta regression 62 sargramostim 62 risperidone Risperdal 62 Acute Decompensated Heart Failure 62 Solorel 62 BLA filing 62 analgesic efficacy 62 severe hypercholesterolemia 62 GOUT 62 AMEVIVE 62 CCR5 inhibitor 62 acromegalic patients 62 eculizumab therapy 62 viral kinetic 62 lucinactant 62 AIR CF3 62 ancrod 62 placebo controlled studies 62 Phase III confirmatory 62 multidose 62 Lofexidine 62 chronic thromboembolic pulmonary 62 ROTARIX 62 orally inhaled migraine 62 sulodexide 62 solithromycin 62 Phase #b/#a trial 62 sorafenib tablets 62 dorzolamide 62 Phenoptin 62 Alinia 62 GLP1 agonist 62 RezularTM 62 blinded randomized controlled 62 IMPACT DCM clinical 62 CTAP# Capsules 62 bolus dose 62 ABSORB trial 62 eosinophilic asthma 62 Pemetrexed 62 Keppra XR 62 GetGoal Phase III 62 TURBT 62 phototoxicity 62 G#DT 62 VICTOR E1 62 multicentre prospective 62 XL# SAR# 62 CELVAPAN H#N# 62 guanfacine extended release 62 adjunctively 62 pharmacokinetic studies 62 bortezomib Velcade 62 velafermin 62 miconazole Lauriad ® 62 Safinamide 62 Phase IIa trial 62 Genasense R oblimersen 62 implantable centrifugal rotary 62 MoxDuo TM IR 62 diarrhea predominant irritable 62 pharmacodynamic profile 62 tumorigenicity 62 nab paclitaxel 62 SPRIX ® 62 Phase Ia 62 torezolid phosphate 62 BENICAR HCT 62 non nucleoside HCV 62 LibiGel Phase III 62 IIa clinical 62 randomized multicenter Phase III 62 fallopian tube cancers 62 controlled multicenter Phase 62 AMPAKINE CX# 62 NeuroSTAT ® 62 tipifarnib 62 hereditary deficiency 62 Dose escalation 62 PEG SN# 62 FDA Investigational Device 62 prospective randomized controlled 62 zonisamide SR 62 oral deforolimus 62 ACOMPLIA R 62 Plicera 62 GSK# [002] 62 Prostate AdenoCarcinoma Treatment 62 BR.# 62 pharmacodynamic properties 62 palifermin 62 colorectal adenoma 62 CA9 SCAN 62 MIST II 62 tanespimycin 62 PhG alpha 1 62 CANCIDAS 62 MDCT scans 62 CLIRS trial 62 pharmacodynamic endpoints 62 systemic hypotension 62 recurrent malignant glioma 62 lumiliximab 62 IV acetaminophen 62 favorable pharmacokinetic profile 62 trials RCTs 62 HDL Selective Delipidation 62 PEGINTRON TM 62 AZILECT R 62 Phase 1a 62 Cariprazine 62 multicenter prospective 62 Interferon beta 1a 62 mertansine 62 Evoltra ® 62 urate lowering 62 NN# [001] 62 AIR CF2 62 myopathy rhabdomyolysis 62 iloprost 62 maximally tolerated dose 62 EEG abnormalities 62 Phase III ADT 62 histone deacetylase inhibitor 62 deferiprone 62 Dalbavancin 62 hypersensitivity allergic reactions 62 6R BH4 62 GERD migraine headaches 62 metastatic malignant 62 STEP BD 62 evaluating mipomersen 62 somatostatin analog 62 perfusion MRI 62 midstage trials 62 Phase 1b clinical trials 62 INSPIRE Trial Phase III 62 clevudine 62 Oral NKTR 62 Degarelix 62 doripenem 62 TYGACIL 62 Saforis 62 Zevalin consolidation 61 Phase 2a clinical 61 XmAb# 61 oral renin inhibitor 61 phase III isavuconazole 61 APTIVUS r 61 daptomycin 61 HCD# [002] 61 Catena ® 61 Egrifta 61 elective PCI 61 Fibrillex TM 61 alagebrium 61 ALVESCO HFA 61 receptor inhibitor 61 O PPDS 61 Initiate Phase 61 Phase 2a clinical trials 61 SPRYCEL ® 61 gemcitabine Gemzar ® 61 immunotherapeutic vaccine 61 liposomal formulation 61 PROCHYMAL 61 posaconazole 61 QTc prolongation 61 ritonavir boosted protease inhibitor 61 aripiprazole Abilify 61 Azedra 61 salmeterol fluticasone 61 SILENOR 61 corticosteroid therapy 61 ritonavir boosting 61 Phase #b/#a clinical 61 randomized controlled clinical trials 61 pramlintide metreleptin 61 levodopa induced dyskinesia 61 pharmacokinetic characteristics 61 ToGA 61 Phase III VISTA 61 daily subcutaneous injections 61 subcutaneously administered 61 Phase III randomized controlled 61 Multicenter Automatic Defibrillator Implantation 61 DCCR 61 Protexia ® 61 temsirolimus Torisel ® 61 octreotide acetate 61 antidiabetic medications 61 Celebrex celecoxib 61 recurrent glioma 61 antibody MAb 61 MoxDuo IR 61 acetonide FA 61 intranasal formulation 61 initiate Phase IIa 61 pramlintide metreleptin combination 61 inhibitor RG# 61 Vidaza azacitidine 61 postmarket surveillance 61 Dual Opioid 61 Pruvel 61 methylnaltrexone 61 serum lipid 61 paroxetine Seroxat 61 ISTODAX 61 uricase 61 radiolabeled TM# 61 OvaRex MAb 61 ocular allergy 61 torcetrapib atorvastatin 61 RELOVAIR ™ 61 Corlux 61 CERVARIX 61 Pre RELAX AHF 61 anagrelide 61 ACTOS ® 61 PREOS R 61 GATTEX ™ 61 ADAGIO study 61 REALITY Trial 61 lexidronam injection 61 Prodarsan 61 Targretin capsules 61 bevirimat Study 61 vapreotide acetate 61 clobazam 61 Initiate Phase II 61 Kynapid 61 Ophena TM 61 mg kg BID 61 CURE AF 61 Randomized Double blind 61 Tasimelteon 61 comparator arm 61 bazedoxifene conjugated estrogens 61 SUTENT ® 61 ENDEAVOR IV 61 rFVIIa 61 subcutaneous PRO 61 alemtuzumab MS 61 sequential dose escalation 61 multicentric 61 ILLUMINATE 61 papillary renal cell carcinoma 61 vidofludimus 61 CUSTOM III 61 SAR# [004] 61 initiate Phase 1b 61 Noxafil 61 LHRH receptor positive 61 Phase #/#a clinical 61 evaluable subjects 61 rhIGF-I/rhIGFBP-3 61 PANVAC VF 61 LEVADEX ™ 61 Cleviprex TM clevidipine 61 evaluating tivozanib 61 docetaxel Taxotere ® 61 olanzapine LAI 61 Pagoclone 61 Active Ulcerative Colitis 61 GATTEX ® 61 NSABP B 61 R#/MEM # 61 Moli# 61 oral salmon calcitonin 61 ongoing Phase IIIb 61 nitrofurantoin 61 fenofibric acid 61 coagulation abnormalities 61 weekly subcutaneous injections 61 rALLy 61 eSVS MESH 61 ORAL Sync 61 RESOLUTE clinical 61 aerosolized KL4 surfactant 61 corifollitropin alfa 61 orally inhaled 61 multicenter multinational 61 GLP toxicology 61 Phase IIb clinical 61 concurrent chemoradiation 61 USL# 61 alefacept 61 Phase 1b trial 61 Arikace 61 CardioFit 61 Exforge HCT 61 intravenous cyclophosphamide 61 zotarolimus 61 oral ridaforolimus 61 Sym# 61 inhaled iloprost 61 Nesiritide 61 confirmatory Phase III 61 multicentre 61 buccal spray 61 lumiracoxib 61 etanercept Enbrel 61 colesevelam HCl 61 PRE SURGE 61 Poly ICLC 61 EP #R 61 AERx iDMS 61 cediranib 61 alicaforsen enema 61 Vascugel ® 61 Lp PLA 2 61 AEGR 61 Ranolazine 61 AZILECT ® 61 ConclusionThis 61 assessing T DM1 61 Aquavan Injection 61 Cimzia ® certolizumab pegol 61 immunotoxicity 61 tezampanel NGX# 61 pharmacodynamic markers 61 Hepatotoxicity 61 Deforolimus 61 dyskinesia PD LID 61 biologic DMARD 61 intravitreal insert 61 INCB# [001] 61 EGS# 61 lenalidomide Revlimid R 61 pharmacodynamic parameters 61 label dose titration 61 Varespladib 61 Multicenter 61 dirucotide MBP# 61 interferon beta 1b 61 Trofex 61 BrachySil 61 histamine dihydrochloride 61 bronchial hyperresponsiveness 61 RhuDex 61 VITAL Trial 61 ENMD # 61 DAPT 61 LibiGel ® 61 Chemophase 61 Aptivus ® 61 vismodegib 61 cobiprostone 61 dosage regimens 61 clinicaltrials 61 biostatistical analysis 61 Dasatinib 61 nucleotide analogue 61 nonclinical studies 61 NovoTTF 61 optimal dosing 61 IIb clinical trial 61 Helicobacter pylori eradication 61 VADT 61 TQT studies 61 TAXUS VI 61 topical formulations 61 AVADO 61 beta2 agonist 61 Perforomist ™ Inhalation Solution 61 EMPHASIS HF trial 61 ACAPODENE 61 Cardiotoxicity 61 PROMACTA 61 Multivariate logistic regression 61 Ceplene/IL-2 61 FOSRENOL ® 61 BrachySil ™ 61 Removab 61 carotid endarterectomy CEA 61 DEEP AF 61 divalproex sodium 61 TORISEL TM 61 Enzastaurin 61 prospective observational cohort 61 QLT Plug Delivery 61 Embolic Protection Device 61 TOLAMBA 61 PREVENT IV 61 ULORIC 61 busulfan 61 Eligen R B# 61 demonstrated antitumor activity 61 optimal dosing regimens 61 Phase III placebo controlled 61 efficacy tolerability 61 ipratropium bromide 61 acyclovir Lauriad ® 61 multicenter placebo controlled 61 rufinamide 61 Insulin PH# 61 intravenous acetaminophen 61 HepDirect prodrug 61 AKT inhibitor 61 Certolizumab pegol 60 Subgroup analysis 60 ascending dose study 60 prelicensure 60 cefazolin 60 RISPERDAL ® 60 KRN# 60 AQ4N 60 Angiox ® 60 Glypromate 60 HQK 60 carcinogenicity study 60 β blockers 60 ARIDOL 60 pharmacokinetic 60 Ophena 60 tarenflurbil 60 diabetic neuropathic pain 60 antiangiogenic agents 60 INVEGA ® 60 Androgel R 60 renal toxicity 60 mITT population 60 ALN VSP Phase 60 TNF antagonist 60 NeuroStar TMS Therapy 60 CRLX# 60 cathepsin K inhibitor 60 ascending doses 60 Mycophenolate Mofetil 60 novel histone deacetylase 60 GRAVITAS trial 60 microdose 60 senicapoc 60 Alequel 60 MVA MUC1 IL2 60 Carotid Revascularization Endarterectomy vs. 60 ALN HPN 60 Tracleer R 60 postintervention 60 Zemiva 60 Study #CL# 60 Archexin 60 TRO# 60 HIV HCV coinfected 60 serum antibody 60 Glycopyrrolate 60 GRNCM1 60 urodynamic 60 Phase 2b clinical 60 electrophysiologic 60 human microdosing 60 RiVax 60 serotonin norepinephrine reuptake inhibitor 60 ANCHOR trial 60 CCR5 mAb 60 phase 2a 60 adenosine injection 60 RRMS patients 60 oral picoplatin 60 Cellegesic 60 ziconotide 60 oral dnaJP1 60 Rezular 60 atorvastatin #mg 60 antiarrhythmic drug 60 doxorubicin docetaxel 60 anti arrhythmic 60 Kamada AAT 60 cetrorelix pamoate 60 inecalcitol 60 FOLOTYN ® 60 transesophageal 60 myelodysplastic myeloproliferative diseases 60 ABILIFY Injection 60 ONGLYZA ™ 60 Telithromycin 60 SCH # 60 pharmacodynamics 60 vivo toxicology 60 FluCAM arm 60 Sapacitabine 60 chest radiographs 60 NEUVENGE 60 beta 1a 60 Levetiracetam 60 EOquin TM 60 certolizumab 60 darunavir r 60 CRESTOR #mg 60 RAPTIVA 60 subcutaneous SC 60 Afatinib 60 Hsp# Inhibitor 60 HGS# 60 heterozygous FH 60 humanised monoclonal antibody 60 Onconase 60 urine albumin 60 rFSH 60 DAVANAT 60 reactogenicity 60 PET tracers 60 Tumor Response 60 NeuroVax 60 PI3K/Akt pathway inhibitor 60 ROCKET AF 60 randomized discontinuation 60 Bioequivalence 60 OLYMPIA registry 60 ADL# novel 60 MEVACOR 60 reteplase 60 Prospective Randomized 60 retrospective cohort 60 postmarketing adverse 60 granted Ortec 60 Omacetaxine mepesuccinate 60 metaglidasen 60 multicenter Phase 60 SCENESSE ® 60 thalidomide Thalomid 60 relapsing remitting MS RRMS 60 SinuNase ™ 60 mesalazine 60 oral antidiabetic medication 60 Gamunex C 60 BCR ABL inhibitor 60 mg/m2 dose 60 keloid scarring 60 miglustat 60 TPI ASM8 60 Serious Adverse Events 60 cinacalcet HCl 60 number NCT# ClinicalTrials.gov 60 gallium nitrate 60 refractory chronic lymphocytic 60 #:# randomization 60 Phase 2a 60 Phase Ib IIa 60 macrolide antibiotic 60 Lymphoseek ® 60 concomitant medications 60 cariprazine 60 bronchodilatory 60 multicenter randomized 60 randomized controlled clinical 60 Rigel R# 60 Cancidas 60 aflibercept VEGF Trap 60 Coronary CTA 60 PreCISe study 60 Exherin TM 60 ELACYT 60 bepotastine besilate nasal spray 60 IMA# 60 TACI Ig 60 cinacalcet 60 endoscopic examinations 60 Tanespimycin 60 Sanvar R 60 biliary tract cancer 60 inhalation toxicology 60 tiagabine 60 Xelox 60 Phase 2b clinical trials 60 SPARLON 60 fostamatinib 60 opioid bowel dysfunction 60 Muraglitazar 60 Phase IIa clinical 60 irbesartan 60 LungAlert TM 60 reduce serum phosphate 60 bardoxolone 60 vivo preclinical 60 candesartan cilexetil 60 indiplon capsules 60 postmarketing surveillance 60 Insulin detemir 60 Progenta TM 60 Aplidin 60 multicentre study 60 doxorubicin cyclophosphamide 60 PRADAXA 60 LCP AtorFen 60 histone deacetylase HDAC inhibitor 60 novel oral anticoagulant 60 rilonacept 60 histrelin 60 ER CHOP 60 ABSSSI 60 HeFH 60 lanthanum carbonate 60 isatoribine 60 LymphoStat B TM 60 Deferiprone 60 initiate multicenter 60 topical testosterone 60 Actimmune ® 60 transcranial Doppler ultrasound 60 metastatic neuroendocrine tumors 60 Phase Ib IIa clinical 60 Cervista HPV HR 60 GEM OS1 60 R#/MEM 60 sorafenib Nexavar 60 ® pioglitazone HCl 60 vaginally administered lidocaine 60 Cethrin R 60 lorcaserin Phase 60 dopaminergic therapy 60 #mg/day [001] 60 Genz # 60 dose escalation trial 60 RSD# 60 CLORETAZINE TM VNP#M 60 PEG INTRON R 60 Alzhemed TM 60 clotrimazole 60 trivalent influenza vaccine 60 Darinaparsin 60 tigecycline 60 VICTOR E3 60 Civacir 60 multicenter trials 60 CYT# potent vascular disrupting 60 HCl capsules 60 convenient dosing regimens 60 opioid naive 60 prospectively randomized 60 Meta analyzes 60 Phase lll 60 cortical stimulation 60 NOXAFIL Oral Suspension 60 Dapagliflozin 60 TMS Therapy 60 APEX AMI trial 60 pheochromocytoma 60 farletuzumab 60 blind placebo 60 MGN# 60 ACTIVE W 60 PS# [001] 60 Carvedilol 60 Voraxaze 60 Velcade bortezomib 60 ceftazidime 60 IPLEX 60 AGILECT R 60 OncoVEX GM CSF 60 sNDA submission